Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD Effects of Low-dose Rivaroxaban with Antiplatelets in CAD/PAD
NCT03718429Phase 4Completed
- Sponsor
- University of Florida
- Start
- Jan 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rivaroxaban in coronary artery disease (CAD), Peripheral Arterial Disease (PAD), sponsored by University of Florida. Started Jan 2019; status: completed.
02
Drugs
rivaroxaban
03
Conditions
coronary artery disease (CAD)Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT03718429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03718429.